[go: up one dir, main page]

HK1222122A1 - 選擇性藥物遞送組合物及使用方法 - Google Patents

選擇性藥物遞送組合物及使用方法

Info

Publication number
HK1222122A1
HK1222122A1 HK16110317.7A HK16110317A HK1222122A1 HK 1222122 A1 HK1222122 A1 HK 1222122A1 HK 16110317 A HK16110317 A HK 16110317A HK 1222122 A1 HK1222122 A1 HK 1222122A1
Authority
HK
Hong Kong
Prior art keywords
methods
drug delivery
delivery compositions
selective drug
selective
Prior art date
Application number
HK16110317.7A
Other languages
English (en)
Inventor
Jesus Gonzalez
Junjie Liu
Marcel Miampamba
Original Assignee
Avelas Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Avelas Biosciences Inc filed Critical Avelas Biosciences Inc
Publication of HK1222122A1 publication Critical patent/HK1222122A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
HK16110317.7A 2013-04-22 2016-08-30 選擇性藥物遞送組合物及使用方法 HK1222122A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361814771P 2013-04-22 2013-04-22
PCT/US2014/035043 WO2014176284A1 (en) 2013-04-22 2014-04-22 Selective drug delivery compositions and methods of use

Publications (1)

Publication Number Publication Date
HK1222122A1 true HK1222122A1 (zh) 2017-06-23

Family

ID=51792348

Family Applications (1)

Application Number Title Priority Date Filing Date
HK16110317.7A HK1222122A1 (zh) 2013-04-22 2016-08-30 選擇性藥物遞送組合物及使用方法

Country Status (4)

Country Link
US (3) US20160082119A1 (zh)
EP (1) EP2988786A4 (zh)
HK (1) HK1222122A1 (zh)
WO (1) WO2014176284A1 (zh)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2732826B1 (en) 2008-01-18 2017-11-08 Visen Medical, Inc. Fluorescent imaging agents
WO2010101628A2 (en) 2009-03-02 2010-09-10 Massachusetts Institute Of Technology Methods and products for in vivo enzyme profiling
AU2012229103A1 (en) 2011-03-15 2013-10-31 Massachusetts Institute Of Technology Multiplexed detection with isotope-coded reporters
CN103874512B (zh) 2011-07-29 2016-11-16 艾维拉斯生物科学公司 选择性递送分子及使用方法
WO2014120974A1 (en) 2013-01-30 2014-08-07 Avelas Biosciences, Inc. Selective delivery molecules and methods of use
ES2828985T3 (es) 2013-06-07 2021-05-28 Massachusetts Inst Technology Detección basada en la afinidad de biomarcadores sintéticos codificados por ligando
CA3214529A1 (en) 2013-09-25 2015-04-02 Cytomx Therapeutics, Inc. Matrix metalloproteinase substrates and other cleavable moieties and methods of use thereof
IL270562B (en) 2014-01-31 2022-08-01 Cytomx Therapeutics Inc Matriptase and u-plasminogen activator polypeptide substrates and other cleanable moieties, compositions comprising same and uses thereof
MA41374A (fr) 2015-01-20 2017-11-28 Cytomx Therapeutics Inc Substrats clivables par métalloprotéase matricielle et clivables par sérine protéase et procédés d'utilisation de ceux-ci
EP3328393B1 (en) * 2015-07-31 2023-12-20 Centrose, Llc Extracellular drug conjugates targeting cd20
AU2016308286B2 (en) 2015-08-18 2022-04-07 Rakuten Medical, Inc. Phthalocyanine dye conjugates and their storage
CN119564879A (zh) 2015-08-18 2025-03-07 乐天医药生技股份有限公司 用于光免疫疗法的组合物、联用及相关方法
WO2017091568A1 (en) 2015-11-23 2017-06-01 Bristol-Myers Squibb Company Additive systems for use in protein pegylation
GB2545169B (en) * 2015-12-01 2019-10-09 Ellipses Pharma Ltd Taxane Prodrug Comprising A Membrane Type Matrix Metalloproteinase Cleavage Site
CN114191563A (zh) 2016-03-02 2022-03-18 卫材研究发展管理有限公司 基于艾日布林的抗体-药物偶联物和使用方法
WO2017177115A1 (en) 2016-04-08 2017-10-12 Massachusetts Institute Of Technology Methods to specifically profile protease activity at lymph nodes
US20190134231A1 (en) * 2016-04-21 2019-05-09 The Board Of Regents Of The University Of Texas System Methods and compositions for detecting aneurysms
CA3022928A1 (en) 2016-05-05 2017-11-09 Massachusetts Institute Of Technology Methods and uses for remotely triggered protease activity measurements
CN107469089B (zh) * 2016-06-07 2022-01-07 北京键凯科技股份有限公司 一种peg连接子及配基药物偶联物
BR112019009019A2 (pt) 2016-11-08 2019-07-09 Regeneron Pharma esteroides e conjugados de proteínas dos mesmos
CN116785450A (zh) * 2017-02-28 2023-09-22 伊缪诺金公司 具有自分解肽接头的类美登素衍生物和其缀合物
CN108623694B (zh) * 2017-03-24 2021-09-17 北京市肿瘤防治研究所 血管内皮细胞生长因子受体拮抗肽f56的衍生物及应用
CA3059358A1 (en) 2017-04-07 2018-10-11 Massachusetts Institute Of Technology Methods to spatially profile protease activity in tissue and sections
JP7364471B2 (ja) 2017-05-18 2023-10-18 レゲネロン ファーマシューティカルス，インコーポレーテッド シクロデキストリンタンパク質薬物コンジュゲート
KR20200085807A (ko) 2017-11-07 2020-07-15 리제너론 파마슈티칼스 인코포레이티드 항체 약물 접합제용 친수성 링커
CA3086926A1 (en) 2018-01-08 2019-07-11 Regeneron Pharmaceuticals, Inc. Steroids and antibody-conjugates thereof
US20220347306A1 (en) * 2018-04-16 2022-11-03 Avelas Biosciences, Inc. Selective delivery of therapeutic and imaging agents
CN108586562B (zh) * 2018-05-08 2019-09-06 苏州博源医疗科技有限公司 一种皮质醇衍生物及其制备方法与应用
CN118955710A (zh) 2018-05-09 2024-11-15 里珍纳龙药品有限公司 抗msr1抗体及其使用方法
WO2020068920A2 (en) 2018-09-25 2020-04-02 Massachusetts Institute Of Technology Lung protease nanosensors and uses thereof
WO2020081493A1 (en) 2018-10-16 2020-04-23 Molecular Templates, Inc. Pd-l1 binding proteins
MY205459A (en) 2018-12-06 2024-10-22 Cytomx Therapeutics Inc Matrix metalloprotease-cleavable and serine or cysteine protease-cleavable substrates and methods of use thereof
US11835522B2 (en) 2019-01-17 2023-12-05 Massachusetts Institute Of Technology Sensors for detecting and imaging of cancer metastasis
CN113874046B (zh) * 2019-01-23 2025-02-28 R.P.谢勒技术有限责任公司 用于抗体-药物缀合物的含有糖苷的肽接头
US12029793B2 (en) 2019-01-28 2024-07-09 Yale University pH low insertion peptide targeted delivery of potent cytotoxic compounds
WO2020176478A1 (en) * 2019-02-25 2020-09-03 The University Of Chicago Methods and compositions for treating inflammatory and autoimmune conditions with ecm-affinity peptides linked to anti-inflammatory agents
SG11202109066RA (en) 2019-03-19 2021-09-29 Fundacio Privada Inst Dinvestigacio Oncològica De Vall Hebron Combination therapy with omomyc and an antibody binding pd-1 or ctla-4 for the treatment of cancer
TW202102272A (zh) 2019-03-29 2021-01-16 美商樂天醫藥生技股份有限公司 光免疫療法之方法及相關之生物標記
WO2021207647A1 (en) * 2020-04-09 2021-10-14 Computational International LLC Small molecule drugs as targeted therapeutics
CA3195591A1 (en) * 2020-10-13 2022-04-21 Jesus E. Gonzalez Methods of using selective delivery molecules
MX2023008341A (es) * 2021-01-15 2023-10-04 Scherer Technologies Llc R P Enlazadores de ésteres de doble escisión para conjugados anticuerpo-fármaco.
CN114522219B (zh) * 2022-02-23 2024-03-26 宜春学院 一种共递送聚合物前药及其制备方法和用途
WO2024089013A1 (en) 2022-10-25 2024-05-02 Peptomyc, S.L. Combination therapy for the treatment of cancer
WO2024251854A1 (en) 2023-06-07 2024-12-12 Fundació Privada Institut D'investigació Oncològica De Vall Hebron Combination therapy with braf inhibitors for the treatment of cancer
WO2024251846A1 (en) 2023-06-07 2024-12-12 Fundació Privada Institut D'investigació Oncològica De Vall Hebron Combination therapy with mek inhibitors for the treatment of cancer
EP4473974A1 (en) 2023-06-07 2024-12-11 Peptomyc, S.L. Omomyc and kras inhibitors combination therapy for the treatment of cancer

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0730472B1 (en) * 1993-11-16 2006-08-02 Bracco International B.V. Immobilized labelling method
US7985401B2 (en) * 2003-10-31 2011-07-26 The Regents Of The University Of California Peptides whose uptake by cells is controllable
EP2732826B1 (en) * 2008-01-18 2017-11-08 Visen Medical, Inc. Fluorescent imaging agents
KR101095841B1 (ko) * 2009-02-19 2011-12-21 주식회사 나이벡 표적 선택적 세포／조직 투과기능 활성을 가지는 펩타이드 및 그 용도
CN102858794A (zh) * 2009-07-15 2013-01-02 加州大学董事会 细胞内吸收可控制的肽
US20130142734A1 (en) * 2010-01-12 2013-06-06 Ayelet David Targeted delivery systems for diagnostic applications
CN103874512B (zh) * 2011-07-29 2016-11-16 艾维拉斯生物科学公司 选择性递送分子及使用方法

Also Published As

Publication number Publication date
EP2988786A4 (en) 2016-12-21
US20200376013A1 (en) 2020-12-03
WO2014176284A1 (en) 2014-10-30
EP2988786A1 (en) 2016-03-02
US20190374560A1 (en) 2019-12-12
US20160082119A1 (en) 2016-03-24

Similar Documents

Publication Publication Date Title
HK1222122A1 (zh) 選擇性藥物遞送組合物及使用方法
HK1254909A1 (zh) 藥物納米粒子的傳送及其使用方法
IL286759A (en) Therapeutic methods and preparations
ZA201506984B (en) Microarray for delivery of therapeutic agent and methods of use
HK1226301A1 (zh) 修飾的治療劑及其組合物
IL244259B (en) Insertion of medical devices
IL240849B (en) Drug delivery devices and drug delivery method
SG10201708522SA (en) Drug delivery devices with drug-permeable component and methods
IL240290A0 (en) History of pyridazinone-amide and pharmaceutical preparations containing them
HK1217720A1 (zh) 選擇性遞送分子及使用方法
SG11201507867RA (en) Antimicrobial compositions and methods of use
HK1220920A1 (zh) 治療性組合物和其用途
HK1221416A1 (zh) 氧雜雙環庚烷和氧雜雙環庚烯的配製品
HK1225645A1 (zh) Pcv2b趨異株疫苗組合物以及使用方法
GB201314312D0 (en) Composition and delivery system
IL239840A0 (en) Polymyxins, preparations, methods of preparation and methods of use
HK1215657A1 (zh) 抗微生物組合物及相關使用方法
IL262252B (en) Medicinal compositions and processes involving mRNA transfection
HK1218079A1 (zh) 亞硝酸鹽的藥物製劑及其用途
HK1219691A1 (zh) 醫藥組成物及其用途
IL240292A0 (en) History of quinazoline and pharmaceutical preparations containing them
HK1222543A1 (zh) 經口藥物遞送裝置和其使用方法
IL244537A0 (en) New administration preparations and methods of their use
GB201307082D0 (en) Pharmaceutical composition comprising 15-HETrE and methods of using the same
GB201319437D0 (en) Delivery of drugs